RICHLAND, WA, May 29, 2012 (MARKETWIRE via COMTEX) –
IsoRay Inc.
/quotes/zigman/387787/quotes/nls/isr ISR
+14.71%
, a medical technology company and
innovator in seed brachytherapy and medical radioisotope
applications, today announced that Discovery Channel has featured the
Company’s Cesium-131 brachytherapy (internal radiation therapy)
treatment for localized prostate cancer.
Discovery Channel Chief Medical Expert John Whyte, MD, MPH, spoke
with UPMC urologist Dr. Ronald Benoit about the advantages of using
Cesium-131 over traditional isotopes. Dr. Benoit explained that UPMC
has been using Cesium-131 over a six year period. UPMC’s study found
that its patients benefited from the minimally invasive treatment
that resulted in reduced urinary problems. Typically, urinary
problems last up to 18 months after treatment with other
brachytherapy options. When using Cesium-131, Dr. Benoit explained,
urinary symptoms were gone in 3 to 6 months. View the Discovery
Channel story here.
One in six men will be diagnosed with prostate cancer during their
lifetimes. It is the second leading cause of cancer deaths among
American men, claiming some 30,000 lives annually. About 1 man in 36
will die of prostate cancer, according to the American Cancer
Society, which reports that about 241,740 new cases of prostate
cancer will be diagnosed in 2012. Only lung cancer claims the lives
of more men each year.
IsoRay is the exclusive manufacturer of Cesium-131. The
ground-breaking brachytherapy treatment represents one of the most
important advancements in internal radiation therapy in 20 years.
Cesium-131 allows for the internal radiation treatment of many
different cancers because of its incomparable combination of high
energy (its unique tissue penetrating capability reaching just far
enough to treat the cancer) and its 9.7 day half-life (its unrivaled
speed in giving off therapeutic radiation). The treatment can be
deployed using several delivery methods including single seed
applicators, implantable strands and mesh, and several new
implantable devices.
IsoRay Chairman and CEO Dwight Babcock commented, “Cesium-131′s
success in treating low and intermediate risk prostate cancer is just
the beginning. IsoRay has built the foundation for the use of
Cesium-131 in the successful treatment of cancers throughout the
body. We expect more physicians and institutions in the medical
community to adopt the use of Cesium-131 for the treatment of
multiple cancers as they become aware of its dramatic impact on
survivability and quality of life benefits for their patients.”
In addition to its CMS codes, Cesium-131 is FDA-cleared in seed form
for the treatment of prostate cancer, lung cancer, ocular melanoma
cancer, brain cancer, colorectal cancer, gynecologic cancer, head and
neck cancer and other cancers throughout the body.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay
Medical, Inc., is the exclusive producer of Cesium-131 internal
radiation therapy, which is expanding brachytherapy options
throughout the body and the GliaSite(R) radiation therapy system, the
world’s only balloon catheter device used in the treatment of brain
cancer. Learn more about this innovative Richland, Washington company
and explore the many benefits and uses of Cesium-131 and the
GliaSite(R) radiation therapy system by visiting
www.isoray.com . Join
us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about
IsoRay’s future expectations, including: the advantages of Cesium-131
seed, whether outcomes, including lessened side effects, from this
study will be experienced by other users of our products, whether
IsoRay will be able to continue to expand its base beyond prostate
cancer, whether IsoRay’s Cesium-131 seed and other delivery methods
for Cesium-131 will be used to successfully treat additional cancers
and malignant disease, whether additional physicians and institutions
will adopt the use of Cesium-131 to treat other cancers will be
successful, and all other statements in this release, other than
historical facts, are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995 (“PSLRA”).
This statement is included for the express purpose of availing
IsoRay, Inc. of the protections of the safe harbor provisions of the
PSLRA. It is important to note that actual results and ultimate
corporate actions could differ materially from those in such
forward-looking statements based on such factors as physician
acceptance, training and use of our products, our ability to
successfully manufacture, market and sell our products, our ability
to manufacture our products in sufficient quantities to meet demand
within required delivery time periods while meeting our quality
control standards, our ability to enforce our intellectual property
rights, whether additional studies are released and support the
conclusions of early clinical studies, whether this and other studies
with Cesium-131 result in favorable patient outcomes, patient results
achieved when Cesium-131 is used for the treatment of cancers and
malignant diseases beyond prostate cancer, successful completion of
future research and development activities, and other risks detailed
from time to time in IsoRay’s reports filed with the SEC.
Contact: Sharon Schultz (301) 351-0109 schultzpr@mchsi.com
SOURCE: IsoRay, Inc.
mailto:schultzpr@mchsi.com
Copyright 2012 Marketwire, Inc., All rights reserved.
/quotes/zigman/387787/quotes/nls/isr
Add to portfolio
ISR
No comments:
Post a Comment